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AbstrAct
Objectives To explore current delays in diagnosis 
of retinoblastoma (Rb) and effect on outcome with 
comparison to a study from the 1990s.
Setting Primary, secondary, tertiary care: majority from 
South of England.
Participants A retrospective analysis of 93 new referrals 
of sporadic (non-familial) Rb to a specialist Rb unit in 
London, UK from January 2006 to February 2014.
Primary and secondary outcomes International 
Intraocular Retinoblastoma Classification, lag times 
including parental delay and healthcare professional delay, 
patients requiring enucleation and requirement of adjuvant 
chemotherapy postenucleation (high-risk Rb).
Results During the study period, 29% presented via 
accident and emergency (A&E). The median referral 
time from symptom onset to visiting primary care (PC) 
was 28 days and PC to ophthalmologist 3 days (range 
0–181 days). The median time from local ophthalmologist 
to the Rb Unit was 6 days (0–33). No significant 
correlation was found between delay and International 
Classification of Retinoblastoma grade (p>0.05) or 
between postenucleation adjuvant chemotherapy and 
enucleation groups (p>0.05). Less enucleations (60%) are 
being performed compared with the previous study (81%) 
(p=0.0015).
Conclusions Parents are attending A&E more compared 
with the 1990s and this may reflect the effect of public 
awareness campaigns. More eyes are being salvaged 
despite a similar number of children requiring adjuvant 
chemotherapy. High-risk Rb and Group E eyes do not 
correlate with increased lag time in the UK. Other 
determinants such as tumour biology may be more 
relevant.
IntroductIon
Delay in diagnosis in paediatric cancers can be 
associated with guilt in families, litigation of 
medical professionals, particularly in primary 
care (PC) and possible poor outcomes.1 Reti-
noblastoma (Rb) is the most common primary 
intraocular malignancy of childhood with 
tumours arising from the developing retina. It 
has been found to be the only paediatric cancer 
associated with poor outcomes due to increased 
lag time (prediagnostic interval). The lag time 
does not seem to decrease over decades for Rb 
and can be divided into parental associated 
delay and healthcare associated delay.1
In resource poor countries, delay in diag-
nosis for Rb is well documented as being 
associated with mortality,2 particularly if there 
is refusal of treatment from parents.3 Over the 
last 20 years, delay in diagnosis in resource 
rich countries, with established PC infrastruc-
tures, has not been associated with increased 
mortality as death is now so rare. However, a 
lengthy delay in diagnosis is associated with 
high-risk Rb (choroidal and/or retrolam-
inar optic nerve invasion) in the UK4 such 
that chemotherapy was required following 
enucleation but not in the USA.5 In addition, 
a trend towards reduced lag time in diag-
nosis was associated with less advanced Rb (in 
terms of classification group) at presentation 
in Switzerland.6
We hypothesise that there is a transition 
over decades in countries such that diagnostic 
delays under 6 months no longer become 
associated with poorer outcomes (such as 
mortality, extraocular disease, histopatholog-
ical high risk features or Group E eyes) due 
to awareness campaigns and improved educa-
tion in PC. As a result, we compared a study in 
the UK from our unit in the 1990s with recent 
findings.
SubjectS and methodS
A retrospective study was designed for 
comparison to a study conducted between 
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Research
Strengths and limitations of this study
 ► Similar numbers of patients were involved in both 
studies (93 in this study and 100 in the paper from 
1999).
 ► This work has major implications for families of 
children with retinoblastoma who are distressed due 
to a potential delay in the referral pathway.
 ► We did not use a questionnaire for parents/carers as 
the answers may have been subjective several years 
after diagnosis, but relied on letters and history 
taken directly before diagnosis.
 ► Genetic analysis, ethnicity and socioeconomic status 
were not assessed in this study.
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Leukocoria noted by parents:
Yes 74 (79.6)
No 19 (20.4)
Age at diagnosis (months):
<6 17 (18.3)
6.1–12 months 22 (23.7)
12.1–24 months 20 (21.5)
















2012–February 2014 32 (34.4)
2009–2011 40 (43.0)
2006–2008 21 (22.6)
1993and 1996 involving children presenting to the Rb Unit 
at St Bartholomew’s, London.4 Consecutive new referrals 
of sporadic cases of Rb to the Royal London Hospital, 
Barts Health NHS Trust, London between January 2006 
and February 2014 were included. Ethical committee 
approval was obtained (#010374). This research adhered 
to the tenets of the Declaration of Helsinki.
Children with a family history of Rb and those with 
dysmorphic features prior to diagnosis were excluded 
as these would not give a true reflection of referral path-
ways. All unilateral or bilateral sporadic cases referred 
were included and classified according to the Interna-
tional Intraocular Retinoblastoma Classification (IIRC).7 
In cases of bilateral Rb, the eye with the higher grade was 
taken as the measure for correlation between delay and 
severity of disease at presentation. The requirement for 
adjuvant chemotherapy was also assessed as this was a key 
finding in the original study.4 The criteria for high-risk 
Rb included histopathological features following enucle-
ation of anterior chamber seeds, scleral invasion, massive 
choroidal or retrolaminar optic nerve invasion.
We were keen to follow a similar methodology to the 
original paper in order that we could compare outcomes. 
Lag times for diagnosis included parental delay and 
Primary Healthcare Professional (PHP) delay.
Lag 1—the time taken from first sign or symptom to 
presentation to PHP; thus, representing ‘parental delay’. 
If several PHPs were consulted, the first PHP according to 
parents/notes was used.
Lag 2—the time from first consultation with PHP to 
first consultation with a local ophthalmologist, thus 
, representing ‘health professional delay’.
Lag 3—the time from local ophthalmologist to Rb unit.
Parental recognition of leukocoria was specifically 
noted along with stage of the tumour and laterality.
Patient participation
The Childhood Eye Cancer Trust (CHECT), a patient 
support group dedicated to the care of children with Rb, 
have asked families of patients if there has been a delay 
in the patient pathway to diagnosis. 19% (unpublished 
data) have informed them that they had difficulty having 
their concerns taken seriously from the initial visit to 
their general practitioner (GP) and often made a repeat 
visit. As a result, they are very interested in the results of 
this work and are keen to disseminate the information to 
all families with Rb.
Statistics
Numerical data were summarised using mean and SD 
or median and range, depending on data distribu-
tion. Categorical data were summarised using count 
and percentages. Data were compared using analysis of 
variance (ANOVA) or its non-parametric equivalent as 
appropriate. Analyses were carried out using Stata V.11. 
No adjustment for multiple testing was made. Therefore, 




A summary of patients’ characteristics is described in 
table 1. A total of 213 notes of patients with Rb presenting 
to the Royal London Hospital Retinoblastoma unit 
between 2006 and 2014 were included in the results. 
One hundred and twenty were excluded due to lack of 
appropriate data regarding the patient journey or due to 
patients being diagnosed from screening. This left 93 chil-
dren who were included in the study. There was a gender 
ratio of roughly 1.5:1 (male:female) with median age at 
the time of first diagnosis 14.7 months (range 1.5–117 
months). Six patients were over the age of 5 years old at 
diagnosis with the eldest diagnosed at 9 years of age.
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Table 2 Lag 2: Referral times (days) from primary healthcare professional to local ophthalmologist
Referral pathway No Mean/days (SD)
Median/
days Range/days Outside 2-week rule
General practitioner (GP) 37 25 (41.4) 7 0–181 11 (29.7%)
Accident and emergency (A&E) 28 2 (5.8) 1 0–31 1 (3.6%)
Health visitor (HV) 7 28 (20.3) 21 1–60 5 (71.4%)
Opticians 10 15 (26.0) 3 1–84 2 (20.0%)
Paediatrician 2 28 1–54 1 (50.0%)
Table 3 Presentation by International Classification of Retinoblastoma grade of disease (not available for one patient)
Stage* N
Mean age at 
presentation/
months (SD) Median age
Laterality of disease (n)†
Median lag /
monthsUnilateral Bilateral
A 0 – – – – –
B 1 – 4.3 1 – 0.2
C 8 24.8 (16.0) 27 6 1 1.55
D 35 21.5 (26.8) 13.8 13 23 1.13
E 48 20.6 (20.7) 12.1 13 35 1.78
*Information on laterality for one stage ‘C’ eye was unavailable.
†In bilateral cases this represents the stage of the more advanced eye.
A total of 69 (74.2%) patients had unilateral disease 
and 24 (25.8%) had bilateral disease. The majority of 
patients were diagnosed at stage D (37.6%) or E (51.6%).
leukocoria
Parents noticed leukocoria in 79.6% of patients (n=74). 
This represents a significant (p<0.05) increase compared 
with the 52% in the period 1993–1996.4
Parental delay (lag 1)
Median time to first visit with a PHP was 28 days or 4 weeks 
(range 0–260 days), although exact data were missing in 
this regard as often records were noted in rough terms of 
whole weeks from first parental concern to visit to PHP. 
This was a longer lag 1 time than previously reported4 
(2.5 weeks).
Practitioner delay (lag 2)
Table 2 presents a summary of referral times to an 
ophthalmologist by source of referral (lag 2). Seven-
ty-three per cent (68 children) were referred within 2 
weeks. The 2-week wait refers to the National Institute 
for Health and Care Excellence which stipulates that the 
recommended referral for a patient with suspect cancer 
should be within 2 weeks.8 Of the total cohort, 37 (40%) 
were referred by GPs, 27 (29%) were brought into acci-
dent and emergency (A&E) by parents (although not 
specified if medical opinion had been sought prior), 9 
(10%) referred by opticians, 6 (6%) by health visitors and 
2 (2%) by paediatricians. Nine children were referred 
directly by consultant ophthalmologists or orthoptists 
within 1 week. The overall median lag 2 time was 3 days: 
previously noted as 14 days.4
age
There was no correlation between age and lag 2 in our 
sample population (Spearman Rank Coefficient 0.06, 
p=0.64). Goddard et al had suggested that there was an 
inverse relationship between age and lag 2.4
lag 3
The median time for referral from ophthalmologist to 
Rb specialist was 6 days (range 0–33 days). Only 2 of 93 
patients were seen by a Rb specialist after a lag of greater 
than 2 weeks. Lag 3  was not recorded previously.4
overall referral times
This is a summation of lag 1, lag 2 and lag 3 encompassing 
the whole patient journey from first symptoms to diag-
nosis. Median referral times were 3 days from primary 
healthcare practitioner to secondary care, with further 
onwards referral time of 6 days from secondary care to a 
Rb specialist. Median referral times from first healthcare 
visit to Rb specialist were 8 days. Overall median referral 
time from first symptoms to diagnosis by a Rb specialist 
was 38 days.
Ten patients had over 6 months overall lag time. Only 
one required adjuvant chemotherapy after enucleation. 
Five were group E and five group D with six unilateral and 
four bilateral.
Stage
Table 3 shows the characteristics of stages at presentation 
to the Rb specialists, using the Murphree classification.7 
There was no statistically significant trend in stage E diag-
noses over the period measured (Pearsons Rank: r=0.31, 
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p=0.61). There was no correlation between stage of 
disease and time to presentation (lag 1) (p=0.57), overall 
lag and need for enucleation (p=0.67), overall lag and 
stage of disease (p=0.57), or age at presentation and stage 
at diagnosis (p=0.64). There was no statistically significant 
difference between lag 1 in patients presenting with stage 
D and stage E disease (p=0.56).
There were no deaths nor extraocular Rb disease 
during the study period.
laterality
A total of 69 (74.2%) patients had unilateral disease and 
24 (25.8%) had bilateral disease. Unilateral disease had 
a significant tendency to present at a later age (mean 
26.5 months) than bilateral disease (mean 14.9 months) 
(p<0.05). The majority of patients were diagnosed at 
stage D (37.6%) or E (51.6%).
Neither lag 1 nor lag 2 were significantly related to 
whether the tumour was unilateral or bilateral (p>0.5). 
There was no statistical difference between laterality and 
D or E disease stage (p>0.2). There were too few C eyes 
to provide accurate comparison between large tumours 
(groups D and E) (83) and group C (8).
enucleation
In 11 of 23 bilateral cases, enucleation was required 
in at least one eye. Of the 70 unilateral cases, 45 were 
treated with primary enucleation. 60% (56 altogether) 
had an enucleation and this compares with 81% (81 of 
100) in the original study. This was statistically different 
(p=0.0015). There was no statistical difference between 
diagnostic delay and patients who were treated with 
enucleation versus those who were treated with primary 
systemic chemotherapy (p>0.05).
adjuvant chemotherapy
Of the 56 patients treated with primary enucleation, 16 
patients (29%) required adjuvant chemotherapy for high-
risk Rb). In the original study, 12 of 100 (12%) patients 
had adjuvant therapy for high-risk Rb compared with 
17% of 93 children in this study using the same criteria 
for adjuvant therapy. A higher proportion of those that 
had enucleation (29%) had high-risk Rb compared the 
1990s (15%) p=0.0496. There was no statistical difference 
between diagnostic delay and patients who were treated 
with adjuvant chemotherapy versus those who were 
treated without adjuvant chemotherapy (p>0.05).
dIScuSSIon
This report seeks to address questions regarding delay 
in diagnosis of Rb with recent outcomes in a socialised 
healthcare system in a developed country. These results 
have implications for counselling individual families, 
targeting education campaigns and healthcare resources, 
as well medicolegal consequences.
We were surprised to note that the median parental 
delay (lag 1) had increased from 2.5 weeks to 4 weeks 
despite multiple public awareness campaigns that had 
been initiated over the last two decades. However, there 
has been a rise in A&E department referrals suggesting 
that the campaigns are having an effect. Parents are 
aware of the importance of leukocoria although false 
positive rates are high.9 It remains unknown whether this 
is related to delays by other PHPs and the parents made 
the decision to take their children to A&E of their own 
volition.
By contrast, the referral from PHPs and A&E to a local 
ophthalmologist (lag 2: doctor/nurse associated lag) 
was shorter at a median of 3 days compared with 2 weeks 
in the 1990s. There appears to be increasing awareness 
among healthcare practitioners regarding the impor-
tance of prompt referral of patients with red flag signs 
of ophthalmic malignancy. The median overall lag to a 
local ophthalmologist (lag 1+lag 2) was 38 days (5 weeks 
3 days) which compares favourably to the the lag of 8 
weeks reported in 1999.4 We did not find any association 
between delay in diagnosis and the requirement for adju-
vant chemotherapy postenucleation.
The results for GPs indicate that of 37 referrals, 11 
(30%) were over 2 weeks. 2 weeks is a UK national target 
for suspected cancer referrals.8 A&E referrals tended to 
be same or next-day referrals with only one outlier. Health 
visitors in this study had a significantly longer median 
referral time (p<0.001) (table 2) suggesting improving 
education to this professional group will reduce lag times 
further. Any delay in the referral of a patient with cancer 
is extremely distressing for the family and in some cases 
there may be medicolegal implications for the PHP.
A gradual shift away from primary enucleation is 
also recognised in this comparison with the 1990s. We 
present figures showing that there has been a statistically 
significant reduction of primary enucleation inpatients 
presenting with sporadic disease compared with a 
decade earlier. Although less primary enucleations are 
performed, a higher proportion have high-risk Rb (29% 
vs 15%). This suggests that the service is avoiding enucle-
ation in patients that the examining ophthalmologists 
(MAR and MSS) consider low risk for metastasis without 
increasing mortality.10
As the evolution of primary healthcare improves, so 
does the role of lag time in the presentation of Rb. It has 
been shown that in countries with high mortality from Rb, 
an increased lag time is associated with death. As mortality 
improves, increased lag time become relevant for surro-
gates of mortality , for example, extraocular disease11 
and metastases.12 Next, it becomes relevant to high-risk 
Rb (including choroidal invasion and/or retrolaminar 
optic nerve invasion) following enucleation4 particularly 
if the lag time is over 6 months.12 Surprisingly, Kaliki et 
al12 found that only 21% of Indian patients with high-risk 
Rb presented after 6 months of signs being noted. This 
suggests other factors are at play for the majority who are 
presenting relatively early to the unit. 6 months is also crit-
ical for an increased risk of advanced intraocular disease: 
E eyes.6 Interestingly, of 10 patients in the UK with over 
6 months delay in diagnosis only one required adjuvant 
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chemotherapy and half did not have Group E disease. 
We have shown that in the UK, high-risk Rb is no longer 
associated with delayed lag time, but a high proportion of 
our patients are still presenting with Group E eyes. This 
group does not have a delayed lag time compared with D 
or C eyes.
Brasme et al1 noted that Rb was the only paediatric 
cancer that was associated with poor outcomes (ie, 
mortality and E eyes) due to increased diagnostic delay. 
Barr felt the ‘delay’ in diagnosis is a misleading concept 
as it is pejorative and a better term is lag time for paedi-
atric cancers.13 The relationship between lag time and 
prognosis is complex and not simply a linear correlation 
between lag time and advanced disease particularly if lag 
times are less than 6 months. We believe that in countries 
with community awareness and good PC resources, Rb 
outcomes are more likely to be determined by tumour 
biology.
lImItatIonS
Goddard et al4 used a questionnaire. We were concerned 
about subjective responses several months/years after 
diagnosis, so we used dates stated in letters and the 
history taken just before diagnosis. We did not assess 
the less advanced eye in bilateral cases. We could not 
compare the change in the proportion of ‘E’ eyes as the 
classification system was not in use in the 1990s nor do 
we have data from the Reese-Ellsworth classification. 
Despite this, we are aware that the proportion of ‘E’ eyes 
is higher than in Switzerland6 (51.6% vs 22.2%) and this 
might reflect different patient pathways in addition to 
children with a family history being excluded in our 
work.
In the UK, screening takes place at birth and at 6 weeks 
of age, with a red reflex test performed by a non-ophthal-
mologist. The primary purpose is to detect cataracts, in 
addition to Rb. As Rb can develop at any time, there is 
an onus on PHPs to assess children appropriately partic-
ularly with the use of a red reflex assessment at any age. 
Detecting early stage Rb (eg, groups A, B and early group 
C) can only be performed by ophthalmologists14 15 with 
children under anaesthesia (as for screening for children 
with genetic mutations) which is why universal screening 
after 6 weeks is not cost-effective and not performed in 
the UK.
We were interested in leukocoria as a presenting sign 
as health education programmes have been directed 
towards this sign. We felt that determining the role of 
squint would require an assessment by an orthoptist at 
presentation and we did not have this robust evaluation 
for all our patients.
A much higher proportion of patients attended A&E, 
but we could not determine in this study if the parents 
went of their own accord or were sent there by the PHP. It 
is possible that their concerns may not have been allayed 
by the PHP and they decided to attend due to public 
awareness.
Since the original study, leukocoria is being detected 
on mobile phones compared with the 1990s and we have 
not analysed whether the leukocoria was detected with 
the naked eye, type of mobile phone or flash photog-
raphy.
Our study was conducted over several years to increase 
the number of patients in this study. In the 1990s, St 
Bartholomew’s Hospital was the only unit in the UK 
seeing patients with Rb, but since 2000 patients have 
been divided between two centres; hence, there has been 
a reduction in the number of patients seen at the Royal 
London Hospital (Barts Health NHS Trust).
Socioeconomic status (SES) and ethnicity16 17 are poten-
tially important factors for the lag time. Our previous 
unpublished data demonstrated that neither ethnicity 
nor SES were strongly associated with advanced group Rb 
in the UK.18 This area needs further exploration as our 
surrogate for SES was based on postcodes and we feel that 
individual family questionnaires would be more accurate.
Another limitation is the lack of RB1 genetic data for 
each patient. Heritable Rb has an earlier age of onset 
compared with non-heritable Rb and it may be relevant 
to the lag time of sporadic cases.
Few studies have looked at the impact of delay in diag-
nosis on vision. This was not looked at in this study. As 
nearly 90% of eyes were stages D or E at presentation and 
these patients would likely have poor vision, the sample 
size for assessment of good vision would be small and the 
results would be unlikely to be statistically significant.
concluSIon
This study adds credence to our hypothesis that while 
important, a linear relationship does not exist between 
lag time and advanced Rb in this cohort where the 
majority of patients presented within 6 months of signs. 
Similar findings have been found in virtually all paedi-
atric cancers.1 Lag time is complex, and we have seen 
children with advanced RB presenting within days of signs 
of leukocoria. The fact that many families are presenting 
to A&E reflects the impact of public awareness campaigns 
and it is essential that they continue.
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